Resources from the same session
277O - The ReSPECT-GBM™ phase I/IIa trial of rhenium-186 nanoliposome (186RNL) in recurrent glioma via convection enhanced delivery (CED) and planned phase IIb trial
Presenter: Andrew Brenner
Session: Proffered Paper session: CNS tumours
Resources:
Abstract
Slides
Webcast
278O - Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295
Presenter: Jian Campian
Session: Proffered Paper session: CNS tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 277O and 278O
Presenter: Giuseppe Minniti
Session: Proffered Paper session: CNS tumours
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: CNS tumours
Resources:
Webcast
279O - ctDNA detection in cerebrospinal fluid and concordance with the primary tumor in a multicenter prospective study of patients with glioma
Presenter: Santiago Cabezas-Camarero
Session: Proffered Paper session: CNS tumours
Resources:
Abstract
Slides
Webcast
280O - Pharmacokinetics and pharmacodynamics of paxalisib in newly diagnosed glioblastoma patients with unmethylated MGMT promoter status: Final phase II study results
Presenter: John de Groot
Session: Proffered Paper session: CNS tumours
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: CNS tumours
Resources:
Webcast